Phio Pharmaceuticals Corp (PHIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has a cash flow conversion efficiency ratio of -0.212x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.08 Million) by net assets ($9.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Phio Pharmaceuticals Corp - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Phio Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PHIO liabilities breakdown for a breakdown of total debt and financial obligations.
Phio Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Playtech Plc
LSE:PTEC
|
-0.001x |
|
Cannabist Company Holdings Inc
NEO:CBST
|
0.245x |
|
Big Pharma Split Corp Class A
TO:PRM
|
-0.011x |
|
Fitzroy River Corporation Ltd
AU:FZR
|
0.062x |
|
Rajshree Sugars & Chemicals Limited
NSE:RAJSREESUG
|
-0.078x |
|
Duketon Mining Ltd
AU:DKM
|
-0.008x |
|
Siam Steel International Public Company Limited
BK:SIAM
|
0.031x |
|
Federal International Holdings Bhd
KLSE:8605
|
0.019x |
Annual Cash Flow Conversion Efficiency for Phio Pharmaceuticals Corp (2011–2024)
The table below shows the annual cash flow conversion efficiency of Phio Pharmaceuticals Corp from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see PHIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.72 Million | $-7.11 Million | -1.506x | -8.29% |
| 2023-12-31 | $7.73 Million | $-10.75 Million | -1.391x | -24.28% |
| 2022-12-31 | $10.84 Million | $-12.13 Million | -1.119x | -106.95% |
| 2021-12-31 | $21.93 Million | $-11.86 Million | -0.541x | +20.04% |
| 2020-12-31 | $13.02 Million | $-8.80 Million | -0.676x | +55.04% |
| 2019-12-31 | $5.75 Million | $-8.64 Million | -1.504x | -171.56% |
| 2018-12-31 | $13.58 Million | $-7.52 Million | -0.554x | +89.33% |
| 2017-12-31 | $1.83 Million | $-9.51 Million | -5.190x | -626.05% |
| 2016-12-31 | $10.86 Million | $-7.76 Million | -0.715x | +13.14% |
| 2015-12-31 | $8.89 Million | $-7.32 Million | -0.823x | +70.88% |
| 2014-12-31 | $2.75 Million | $-7.76 Million | -2.826x | -121.32% |
| 2013-12-31 | $4.94 Million | $-6.31 Million | -1.277x | -247.33% |
| 2012-12-31 | $-5.84 Million | $-5.06 Million | 0.867x | -94.91% |
| 2011-12-31 | $-587.00K | $-9.99 Million | 17.017x | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double posi… Read more